UNSPSC 51112521: Prednimustine

This classification denotes a nitrogen mustard compound with the molecular formula C35H45Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9403SIO2S8, chemically known as 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate) but more generally known as prednimustine, which bears US NIH Compound Identifier 34457. European Medicines Agency schedules Prednimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10016MIG.

UNSPSC 51112521 Prednimustine is a Commodity code covering a specific pharmaceutical product used in state and local health benefit programs. The Texas Health and Human Services Commission is currently gathering market intelligence on direct-to-manufacturer prescription programs that could incorporate this and other medications into state pharmacy benefit delivery, moving away from traditional pharmacy benefit manager and group purchasing organization intermediation. State and local governments procure prednimustine primarily through pharmacy benefit programs serving employee group health plans, Medicaid, and other state-administered healthcare coverage. Issuing bodies for this code span state health and human services departments managing pharmacy benefits for public employees and eligible populations.

The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment. The RFI is exploratory, designed to inform future procurement strategy before a formal RFP; no award value, budget, or binding timelines are established. The state is evaluating vendors' experience with direct contracting for self-insured employers and health plans, their ability to negotiate net pricing models without rebates, and capacity for value-based or outcomes-based agreements. This activity signals Texas HHS intent to restructure pharmacy procurement channels, potentially creating opportunities for vendors capable of direct manufacturer relationships and alternative pricing arrangements outside conventional PBM and GPO structures.